Abstract:Background:Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication of systemic juvenile idiopathic arthritis (SJIA). However, early recognition of MAS remains challenging. Because it is clinically heterogeneous, hemophagocytosis is often not detected, and histopathological features lack the specificity associated with hemophagocytic syndromes. In addition, it is often difficult to distinguish early MAS from SJIA or sepsis-like syndromes.Objectives:To identify early clinical and laboratory characteristics of MAS associated with SJIA.Methods:This is a retrospective cohort study of 149 SJIA patients treated at the Children’s Hospital of Zhejiang University School of Medicine between January 2010 to December 2017. All patients fulfilled 2001 ILAR criteria for SJIA, and 27 fulfilled 2016 Classification Criteria for MAS. We evaluated the clinical and laboratory features of SJIA patients with MAS and compared them to those without MAS. We focused our analysis on early MAS, which was defined as the time when the initial clinical and/or laboratory abnormalities suggestive of MAS were first detected.Results:The clinical features associated with early MAS were hypotension, absence of arthritis and lymphadenopathy, bone marrow hemophagocytosis, central nervous system dysfunction, and gastrointestinal involvement. The best laboratory parameters for early MAS detection were platelet counts ≤275.0 × 109/L, lactate dehydrogenase >596.0 U/L, aspartate aminotransferase >47.0 U/L, erythrocyte sedimentation rates ≤41.0 mm/h, ferritin >1400.0 ng/mL, D-dimer >1.40 mg/L, triglyceride >1.30 mmol/L, alanine aminotransferase >33.0 U/L, C-reactive protein ≤68.0 mg/L, fibrinogen ≤4.1 g/L, absolute neutrophil counts ≤5.2 × 109/L, serum total protein ≤66.0 g/L, and white blood cell ≤9.8 × 109/L. The combination of cytokines of IFN-γ >17.1 pg/mL and IL-10 >7.8 pg/mL were found to be a specific and good prognostic cytokine pattern for early recognition of MAS, the sensitivity and specificity as 71.4% and 98.2%.(Table 1, Fig 1, 2)Table 1.Identification of clinical and Cytokine characteristics differentiating patients with MAS onset from SJIA patients without MASCharacteristicsSensitivity (%)Specificity (%)OR (95% CI)p valueClinical characteristicsHypotension35.598.433.0 (6.8–160.1)0.000Absence of Arthritis77.485.219.8 (7.4–52.7)0.000Hemophagocytosis in the bone marrow28.697.314.5 (2.0–107.5)0.009Central nervous system involvement25.891.03.5 (1.3–9.7)0.015Gastrointestinal involvement22.691.83.3 (1.1–9.4)0.029Absence of lymphadenopathy77.451.62.6 (1.1–6.1)0.027Cytokine levelsIFN-γ >17.1 pg/mL82.183.649.5 (15.6–156.9)0.000IL-10 >7.8 pg/mL78.693.123.5 (7.9–69.5)0.000IFN-γ >17.1 pg/mL and IL-10 >7.8 pg/mL71.498.2142.5 (28.2–720.6)0.000OR, odds ratio. CI, confidence interval. PLT, platelet. LDH, lactate dehydrogenase. AST, aspartate aminotransferase. ESR, erythrocyte sedimentation rate. FER, ferritin. D-D, D-dimer. TG, triglycerides. ALT, alanine aminotransferase. CRP, C-reactive protein. FIB, fibrinogen. ANC, absolute neutrophil count; TP, total protein. WBC, white blood cells. ALB, albumin. IL, interleukin. IFN, interferon.Fig 1.Comparison of clinical characteristics in the MAS process. * P < 0.05. ** P < 0.01. CNS involvement: Central nervous system involvement.Fig 2.Comparison of serum cytokine levels in the MAS process. * P < 0.05. ** P < 0.01.Conclusion:Sudden hypotension, absence of arthritis, and significantly increased IFN-γ and IL-10 levels are important clinical and laboratory markers for early MAS identification in addition to the traditional features of SJIA-associated MAS.References:(not show references here)Disclosure of Interests:None declared

Laboratory Features and Pathology of Cytokine Storm Syndromes

Understanding of Cytokines and Targeted Therapy in Macrophage Activation Syndrome.

Clinical and Laboratory Features of Macrophage Activation Syndrome

Clinical and Laboratory Features, Treatment, and Outcomes of Macrophage Activation Syndrome in 80 Children: a Multi-Center Study in China

FRI0463 IDENTIFICATION OF EARLY CLINICAL AND LABORATORY CHARACTERISTICS OF MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Criteria for Cytokine Storm Syndromes

Other Immunomodulatory Treatment for Cytokine Storm Syndromes

Systemic Lupus Erythematosus and Cytokine Storm

Unleashing the Cytokine Storm: A Case of Macrophage Activation Syndrome in Systemic Lupus Erythematosus

Cytokines in Cytokine Storm Syndrome

Bacteria-Associated Cytokine Storm Syndrome

Clinical Features of Cytokine Storm Syndrome

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes

Monocytic Phagocytes in the Immunopathogenesis of Cytokine Storm Syndromes

Cytokine Storm Syndrome Associated with Hemorrhagic Fever and Other Viruses

Macrophage Activation Syndrome in Children: Update on Diagnosis and Treatment

Connective tissue disease with macrophage activation syndrome: A case report

Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments

Parasitic and Fungal Triggers of Cytokine Storm Syndrome

Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: two rare sides of the same devastating coin

Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome